Demand for glucagon-like peptide-1 weight-loss drugs — such as Ozempic, Zepbound and Wegovy — coupled with limited insurance coverage has fueled a risky but growing “gray” market for purchasing active ...

Tirzepatide was superior to semaglutide in achieving standard and intensive cardiometabolic targets among patients with type 2 diabetes.

Baseline BMI may play a significant role in improving exercise capacity, body weight and BP among patients with HF with ...

In a recent study published in Life Metabolism, researchers at Fudan University report that even after stopping the anti-obesity drug tirzepatide, Chinese obese individuals can maintain significant ...

Explore the evolving US housing market: trends in homebuilder confidence, construction growth, renter vs. owner dynamics, and the impact of tariffs on costs.

ENDO 2025 Tirzepatide Outperforms Semaglutide on Combined T2D Goals Tirzepatide outperformed semaglutide in simultaneously achieving four key therapeutic targets for type 2 diabetes.